comments formfghfgh new version

8/10/2019 Comments Formfghfgh New Version

1/3

Comments Form

Page no 1

we welcome to our journal International Journal of Pharma and Biosciences (www.ijpbs.net). Kindly re iew the manuscript and pro ideyour aluable comments!su""estion in the pa"e # of this $% word

document. &nce the author re ises the manuscript based on yourcomments ' indly ensure if those comments are recti ed and thenpro ide your si"nature below and ad ice the author to send there ised manuscript alon" with this form (scan and send us the pa"e #only) .*e sincerely than and appreciate your sincere ser ice inre iewin" this manuscript.

For ReviewersAttention !

*e ha e recei ed your research!re iew article. *e would be sendin" your manuscriptto our re iewer (+e iewer ,) for e aluation. *e need your paper also to be re iewed by another+e iewer (+e iewer #) of your choice. %o *e ha e also sent a copy of your manuscript with thisemail. -his re iewer (+e iewer #) should be Ph. ! $. .!$.%!/ead of the institute or colle"e. -hisre iewer should be an e0pertise!speciali1ed in your manuscript eld of interest and should notbe any of the authors of your submitted manuscript. In page 2 of this *ord document ' youcan nd comments!%u""estion cum 2ppro al of re iewer 3# form. 4et thecomment!%u""estion from the re iewer(+e iewer3#) and re ise your manuscript (If there isany ne"ati e comments) and "et si"nature from the +e iewer . -hen send the completed!si"nedcomments!%u""estion cum 2ppro al of re iewer 3# form and re ised manuscript to us.

Decision of provisional acceptance will be taken within 4- a"s fromthe ate of receiving this form# $o o not ela"#

Re iewer # is to be selected by the author and should be a Ph. ! $. .((more than e years of e0perience)!$.% !/eadof the institute or colle"e .-he re iewer should be e0pertise!speciali1ed in your manuscript eld of interest and shouldnot be any of the authors of the manuscript.

%f "o& have an" '&erries o email &s e itori(pbs)re i*mail#com + e itoro,(pbs)"ahoo#com or. prasmol)re i*mail#com or . call /00 02 0 %n ia. or. 30100 02 0 Abroa .

For A&thorsAttention !
mailto:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]


2/3

Comments $&ggestions c&m Approval of Reviewer 2

5itle of the man&script - (write or type the manuscript title below)

ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THEQUANTITATIVE ESTIMATION OF NIMBIN IN BULK AND SOLID DOSAGE

FORM BY RP-HPLC #################################################################################################################################

Page6&mbe

rComments $&ggestions

3 Introduction previous attempts for the estimation of nimbin should be reportedand then your motive for current method development can be justified. These thinswill be better to justify the need of the problem.

4 Optimization of Chromato raphic Conditions! "uthor wrote #The mobile phaseconsistin of methanol$ acetonitrile and %& O'" were( but in abstract authormention different mobile phase.

) Chec* re ression e+uation on pa e ) and in abstract. Its not same.,% -ormulation "ssay results can be added to abstract,) In conclusion part$ present result should be compared with previous results so that

author can show si nificance of development of present method.7ore Row pages can be incl& e if these rows page is ins&8cient for the

Comments $&ggestions.

33333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333Declaration of the Reviewer Reviewer2.

+espected 5ditor' 2s per your re6uest' i ha e re iewed the manuscript

Page no 2

7ame with 8uali cation r. %ubhash 9. $andalesi"nation andepartment

2ssociate Professor' epartment of Pharmaceutical -echnolo"y

:ield of50pertise!Interest

Pharmaco"nosy

2ddress of the Institute

epartment of Pharmaceutical -echnolo"y' Jada pur ;ni ersity' Kol ata3#.

5mail Id subhashmandal?yahoo.comPhone ($obile @!orAand line)

= C>>= D>


3/3

"nalytical method development and validation for the +uantitative estimation of nimbin in bul* and soliddosa e form by '!/'0C submitted by 1"2I I1 "/5" -"OO6 I (correspondin"author). -he comments!su""estions "i en abo e by me on this comments and su""estionform has been recti ed by the author and found satisfactory to the best of my nowled"e ande0pertise and ha e ad ised the author to resubmit the re iewed paper alon" with the list ofcomments!su""estions (pa"e #). I authorise and recommend the correspondin" author forsubmission of this re iewed manuscript to International Journal of Pharma and Bio %ciencestowards publication. I also ta e personal responsibility o er this manuscript for its 6uality forpublication. If any future liti"ation arises after publication' I and authors would be responsibleand would cooperate with the decision of the $ana"in" 5ditor of this journal.

r. %ubhash 9.$andal

Page no 9

%i"nature of the +e iewer(&Ecial seal)

comments formfghfgh new version

Documents